Table 1

Patients’ characteristics at LM diagnosis
Number of inclusion Age at BC diagnosis BC characteristics Age at LM diagnosis Clinical symptoms Biochemical CSF analysis Cytological CSF analysis Neuraxis MRI
03 56 Undifferenciated carcinoma, HPG 3, ER-, PR -, HER2- 60 Cognitive disorders Proteinorachia: 0.24 g/l Presence of malignant cells LM involvement
Glycorachia: 2.7 Brain metastases
Chlorurorachia: 118
05 61 ILC, HPG 2, ER+, PR+, HER2- 61 Dizziness Proteinorachia: 2.19 g/l Presence of malignant cells LM involvement
Glycorachia: 1.7 No brain metastases
Chlorurorachia: 124
06 53 Adenocarcinoma, HPG 2, ER+, PR+, HER2 - 74 None Proteinorachia: 0.48 g/l Presence of malignant cells LM involvement
Glycorachia: 3.5 No brain metastases
Chlorurorachia: 123
09 42 Adenocarcinoma, HPG 2, ER+, PR +, HER2 - 60 Dizziness, deafness Proteinorachia: 1.49 g/l Presence of malignant cells LM involvement
Glycorachia: 2.7 No brain metastases
Chlorurorachia: 116
10 47 IDC, HPG 2, ER+, PR+, HER2- 59 Visual disorders Proteinorachia: 0.51 g/l Presence of malignant cells LM involvement
Glycorachia: 4.0 Brain metastases
Chlorurorachia: 120
11 41 ICL, HPG 3, ER+, PR -, HER2 + 45 Cauda equine syndrome Proteinorachia: 7.08 g/l Presence of malignant cells LM involvement
Glycorachia: 2 Brain metastases
Chlorurorachia: 113
12 44 IDC, HPG 2, ER+, PR+, HER2 + 57 None Proteinorachia: 0.28 g/l Presence of malignant cells LM involvement
Glycorachia: 4.9 Brain metastases
Chlorurorachia: 120
13 45 Undifferenciated carcinoma, HPG 3, ER+, PR+, HER2 - 50 Cauda equina syndrome Proteinorachia: 5.80 g/l Presence of malignant cells LM involvement
Glycorachia: 3.6 Brain metastases
Chlorurorachia: 111

LM Leptomeningeal Metastases, CSF Cerebro Spinal Fluid, TC Tumor Cells, ILC Invasive Lobular Carcinoma, IDC Invasive Ductal Carcinoma, HPG histoprognostic grade, ER Estrogen Receptors, PR Progesterone Receptors, HER2 Human Epidermal Growth Factor Receptor-2, TTF1 Thyroid Transcription Factor 1, EGFR Epidermal Growth Factor Receptor, CNS Central Nervous System, MRI Magnetic Resonance Imaging, IT IntraThecal.

Le Rhun et al.

Le Rhun et al. BMC Clinical Pathology 2012 12:21   doi:10.1186/1472-6890-12-21

Open Data